Health Care [ 9/12 ] | Health Care Equipment & Supplies [ 46/76 ]
NASDAQ | Common Stock
Biomerica, Inc., a biomedical technology company, engages in developing, patenting, manufacturing, and marketing diagnostic and therapeutic products for the detection and treatment of medical conditions and diseases worldwide.
The company's diagnostic test kits are used to analyze blood, urine, nasal or fecal specimens from patients in the diagnosis of various diseases, food intolerances, and other medical complications, as well as to measure the levels of specific bacteria, hormones, antibodies, antigens, and other substances which may exist in the human body, stools, or blood in extremely small concentrations.
It primarily sells its products for treating gastrointestinal diseases and food intolerances, as well as various esoteric tests at the physicians' offices and over-the-counter drugstores, and hospital/clinical laboratories.
The company is also involved in the development of InFoods IBS, that uses a simple blood sample to identify patient-specific foods which may alleviate irritable bowel syndrome symptoms; and hp+detect, a H.
Pylori diagnostic test that indicates if a patient is infected with the H.
Pylori bacteria.
In addition, it develops, markets, and sells COVID-19 diagnostic tests to indicate if a person has been infected by COVID-19.
The company was incorporated in 1971 and is headquartered in Irvine, California.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Apr 12, 24 | -0.11 Increased by +5.00% | - |
| Jan 16, 24 | -0.09 Increased by +25.33% | 0.04 Decreased by -324.00% |
| Oct 12, 23 | -0.11 Increased by +33.44% | -0.02 Decreased by -432.50% |
| Aug 25, 23 | -0.11 Increased by +21.43% | -0.08 Decreased by -37.50% |
| Apr 14, 23 | -0.12 Decreased by -1.10 K% | 0.02 Decreased by -700.00% |
| Jan 13, 23 | -0.12 Decreased by -33.33% | - |
| Oct 13, 22 | -0.16 Decreased by -33.33% | -0.02 Decreased by -700.00% |
| Aug 29, 22 | -0.14 Decreased by -16.67% | -0.12 Decreased by -16.67% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Aug 31, 24 | 1.81 M Increased by +5.49% | -1.32 M Decreased by -16.25% | Decreased by -72.83% Decreased by -10.21% |
| May 31, 24 | 1.12 M Increased by +0.70% | -1.42 M Increased by +20.71% | Decreased by -127.33% Increased by +21.26% |
| Feb 29, 24 | 1.02 M Decreased by -8.50% | -1.92 M Decreased by -16.25% | Decreased by -188.59% Decreased by -27.05% |
| Nov 30, 23 | 1.57 M Increased by +5.74% | -1.51 M Increased by +7.32% | Decreased by -96.17% Increased by +12.36% |
| Aug 31, 23 | 1.71 M Increased by +4.61% | -1.13 M Increased by +45.36% | Decreased by -66.08% Increased by +47.77% |
| May 31, 23 | 1.11 M Decreased by -79.10% | -1.79 M Decreased by -1.88% | Decreased by -161.72% Decreased by -387.47% |
| Feb 28, 23 | 1.11 M Decreased by -85.49% | -1.65 M Decreased by -1.48 K% | Decreased by -148.44% Decreased by -10.82 K% |
| Nov 30, 22 | 1.48 M Decreased by -68.11% | -1.63 M Decreased by -44.51% | Decreased by -109.73% Decreased by -353.13% |